Growth Opportunities and Trends in the Tremfya Market: Key Insights for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the tremfya market?
In recent times, the Tremfya market has seen an XX (HCAGR) increase in its size. Its growth is anticipated to rise from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. The historical growth of the market can be attributed to a surge in cases of psoriasis and psoriatic arthritis, amplified focus on tailored therapies, increase in healthcare investments, a rise in specialty clinics, and broader acceptance of biologics in dermatology and rheumatology.
What will be the tremfya market size in the future?
The market size of tremfya is anticipated to witness a compound annual growth rate (FCAGR) of XX% in the upcoming years, expanding to $XX million in 2029. Factors contributing to this projected growth during the forecast period include the expansion of healthcare facilities, the growing acceptance of point-of-care testing, increased funding in healthcare research, and an escalated emphasis on precision medicine. The forecast period is also expected to see major trends including advancements in treatment modalities, personalized medicine strategies, the incorporation of technology in patient monitoring, the use of artificial intelligence (AI), and progressive improvements in injection devices.
Get your tremfya market report here!
https://www.thebusinessresearchcompany.com/report/tremfya-global-market-report
What main drivers are fueling expansion in the tremfya market?
The escalating occurrence of autoimmune diseases, where the body’s immune system wrongly attacks its own cells, tissues, or organs, as it perceives them as alien invaders, is predicted to surge the growth of the tremfya market. Numerous factors such as genetic predisposition, environmental elements, alterations in lifestyle, enhanced awareness, and bettered diagnostic capabilities contribute to the growing prevalence of these diseases. Tremfya, a monoclonal antibody that targets interleukin-23 (IL-23), diminishes inflammation and eases symptoms in conditions like psoriasis and psoriatic arthritis by controlling the immune system’s hyperactive response. For example, Australian Institute of Health and Welfare reported in June 2024 that hospitalizations in Australia for rheumatoid arthritis saw a 25% raise to 10,000 in 2022, from 8,000 in the previous year, constituting a rate of 39 per 100,000 people. Consequently, the soaring prevalence of autoimmune diseases is fuelling the tremfya market’s expansion.
What key areas define the segmentation of the global tremfya market?
The tremfya market covered in this report is segmented –
1) By Indication: Moderate-To-Severe Plaque Psoriasis; Active PsA
2) By Formulation: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By End User: Adult Patients; Geriatric Patients
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20343&type=smp
Who are the dominant players expanding their reach in the tremfya market?
Major companies operating in the tremfya market are Johnson & Johnson
How are evolving market trends shaping tremfya Strategies?
The prominent trend in the tremfya market revolves around securing regulatory approvals to extend its therapeutic uses. This includes treating moderate-to-severe Crohn’s disease, thereby widening its patient demographic and the potential market. Regulatory approvals are official permissions provided by governing bodies like the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These approvals allow a medication to be marketed for specific uses after proving its safety, effectiveness, and quality. An example occurred in September 2024, when Johnson & Johnson, a pharmaceutical company based in the US, received FDA approval for TREMFYA (guselkumab). It was approved to treat adults with moderately to severely active ulcerative colitis, registering it as the first dual-acting interleukin-23 inhibitor authorized for this ailment. This decision was founded on positive outcomes from the Phase 2b/3 QUASAR trial, demonstrating that about 50% of patients achieved clinical remission after 44 weeks of treatment. TREMFYA aims at interleukin-23, aiding in regularising the inflammatory response in the colon.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20343
Which regions are emerging as leaders in the tremfya market?
North America was the largest region in the tremfy market in 2024. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Inflammatory Bowel Disease Treatment Global Market Report 2025
Non-Steroidal Anti-inflammatory Drugs Global Market Report 2025
Anti-Inflammatory Therapeutics Global Market Report 2025
https://thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
